Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001204745 | SCV001375965 | uncertain significance | Saldino-Mainzer syndrome | 2022-06-22 | criteria provided, single submitter | clinical testing | This sequence change replaces glutamic acid, which is acidic and polar, with glycine, which is neutral and non-polar, at codon 1232 of the IFT140 protein (p.Glu1232Gly). This variant is present in population databases (rs774000109, gnomAD 0.02%). This variant has not been reported in the literature in individuals affected with IFT140-related conditions. ClinVar contains an entry for this variant (Variation ID: 936029). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV004986941 | SCV005604231 | uncertain significance | Inborn genetic diseases | 2024-09-10 | criteria provided, single submitter | clinical testing | The c.3695A>G (p.E1232G) alteration is located in exon 28 (coding exon 26) of the IFT140 gene. This alteration results from a A to G substitution at nucleotide position 3695, causing the glutamic acid (E) at amino acid position 1232 to be replaced by a glycine (G). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Fulgent Genetics, |
RCV005012603 | SCV005642717 | uncertain significance | Saldino-Mainzer syndrome; Retinitis pigmentosa 80 | 2024-04-20 | criteria provided, single submitter | clinical testing |